Skip to Main Content

Paper Details

Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.
Diabetes Res Clin Pract
0
2022
Author NameAffiliation
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School
Elisabetta PatornoDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School
  • 1 - 2

Datasets

Release 1.2